First Living-Drug CAR-T Studies in Solid Organ Cancers Show Promise

At the Society for Immunotherapy of Cancer's November 2019 annual meeting, its 34th, the first living-drug CAR-T immunotherapy clinical trial targeting solid organ tumors was announced. Chimeric antigen receptor T-cell (CAR-T) therapy emerged recently as a new approach, but success has mainly involved hematological cancers, particularly B-cell malignancies because CAR-T can eliminate all B cells. In solid tumors such as lung, breast, and colon cancer, identifying a target protein present only in cancer cells and absent from healthy cellshas limited CAR-T therapy, since targeting healthy cells harms survival. Researchers identified a protein masked in healthy cells but abundant in cancer cells,MUC1-C, and moved this knowledge into clinical trials. Earlier studies targeted the entire tandem repeat domains of MUC1 (transmembrane glycoprotein mucin-1), unsuccessfully. MUC1 protein's outer-facing repeat domains are cleaved and shed from cancer-cell surfaces, increasingly as tumors advance. After MUC1 cleavage and shedding, the remaining transmembrane segment is called MUC1-C (MUC1*). MUC1-C emergence can make tumors chemotherapy-resistant because onco-embryonic growth factor binds MUC1-C and activates MUC1-C. MUC1-C in the breast cancer microenvironment arises when matrix metalloproteinase 9 cleaves full-length MUC1. Healthy-cell MUC1 is cleaved by different matrix metalloproteinases. Consequently, MUC1-C becomes a cancer-cell-specific target . In animal models, the treatment bound breast cancer cells at %95, ovarian at %83, pancreatic at %78, and lung at %71, leading to human trials. High cost is a major obstacle to wider CAR-T use. If trials succeed, necessary efforts will also seek lower costs.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.